uniQure Announces Presentations at Upcoming April Conferences
April 03 2017 - 7:00AM
uniQure N.V. (NASDAQ:QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced presentations at the following conferences
taking place in April:
World Orphan Drug Congress USA, April 19
– 21 2017, at the Washington Marriott Wardman Park in Washington
D.C.
- Matt Kapusta, Chief Executive Officer, will be presenting a
keynote address: Adeno-associated virus (AAV)-based gene therapies
for rare, chronic and degenerative diseases, on Friday April 21st,
2017, 9.40 a.m. EDT.
12th Annual HD Therapeutics Conference
by CHDI, April 24 – 27 2017, at the Westin Dragonara Resort in St.
Julian’s, Malta.
- A presentation new preclinical data on huntingtin gene
silencing in a mini-pig model of Huntington’s Disease, using
allele-specific and non-selective miRNAs, will be presented during
the CHDI conference.
Gene Therapy for Rare Disorders
Conference, April 25 – 26 2017, at the Sheraton Boston Hotel, in
Boston MA.
- Lance Weed, Vice President of US Operations, will be
presenting: Optimizing the Scalability of Gene Therapy
Manufacturing, on Tuesday April 25th, 2017, 2.00 p.m. EDT.
- Eileen Sawyer, Director of Global Medical Affairs, will be
presenting: Bridging Gaps Through Early Integration of the Internal
Medical Affairs Function, on Wednesday April 26th, 2017, 11.00 a.m.
EDT.
- Daniel Leonard, Director of Global Patient Advocacy, will be
presenting: The Intersection of Patient Advocacy and Gene Therapy:
A Case Study in Hemophilia, on Wednesday April 26th, 2017, 2.00
p.m. EDT.
Alliance for Regenerative Medicines
(ARM)’s 5th Annual Cell & Gene Therapy Investor Day, April 27th
2017, at The State Room, in Boston MA.
- Matthew Kapusta, chief executive officer, will be participating
in a fireside chat on Thursday, April 27th, 2017, 2.15 p.m.
EDT.
The Company also announced its participation in
the following conferences taking place in April:
Hemophilia Federation of America (HFA)’s
Annual Symposium, April 6 – 9 2017, at the Rhode Island Convention
Center in Providence, RI.
The International Liver Congress 2017 by
EASL, April 19 – 23 2017 at the RAI in Amsterdam, The
Netherlands.
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary and partnered gene therapies to treat patients with
hemophilia, Huntington’s disease and cardiovascular diseases.
www.uniQure.com
uniQure Contacts:
Maria E. Cantor
Direct: 339-970-7536
Mobile: 617-680-9452
m.cantor@uniQure.com
Eva M. Mulder
Direct: +31 20 240 6103
Mobile: +31 6 52 33 15 79
e.mulder@uniQure.com
Tom Malone
Direct: 339-970-7558
Mobile: 339-223-8541
t.malone@uniQure.com
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024